Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference
01 Agosto 2023 - 9:00AM
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development, and commercialization of targeted therapies
for women’s cancers, today announced that Sean P. Bohen, M.D.,
Ph.D., President and Chief Executive Officer, will participate in a
Fireside Chat at the Canaccord Genuity 43rd Annual Growth
Conference in Boston on Wednesday, August 9, 2023, at 2:00 p.m. ET.
A live webcast of the Fireside Chat and any
accompanying presentation materials will be available under the
News & Events section of Olema’s investor relations website at
www.olema.com. The webcast will be archived for at least 30
days.
About Olema OncologyOlema Oncology
is a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of targeted therapies
for women’s cancers. Olema’s lead product candidate, OP-1250, is a
proprietary, orally-available small molecule with dual activity as
both a complete estrogen receptor (ER) antagonist (CERAN) and a
selective ER degrader (SERD). It is currently being evaluated both
as a single agent in an ongoing Phase 2 clinical trial, and in
combination with CDK4/6 inhibitors (palbociclib and ribociclib) and
a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally
advanced or metastatic ER-positive (ER+), human epidermal growth
factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been
granted FDA Fast Track designation for the treatment of ER+/HER2-
metastatic breast cancer that has progressed following one or more
lines of endocrine therapy with at least one line given in
combination with a CDK4/6 inhibitor. Olema is headquartered in San
Francisco and has operations in Cambridge, Massachusetts.
IR Contact:Shane Kovacs, Chief Operating and
Financial Officerir@olema.com
Media Contact:Ignacio Guerrero-Ros, Ph.D., Russo
Partners646-942-5604ignacio.guerrero-ros@russopartnersllc.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024